Mounjaro 7.5MG Pen (Tirzepatide 7.5 mg)

Composition:
Tirzepatide 7.5 mg in a sterile, pre-filled injection pen intended for subcutaneous administration once weekly.

Description:
Mounjaro 7.5mg Injection contains Tirzepatide, a dual GIP and GLP-1 receptor agonist used for glycemic control in adults with type 2 diabetes. It improves insulin secretion, reduces glucagon levels, slows gastric emptying, and enhances satiety, leading to improved blood sugar control and potential weight reduction. This strength is commonly used after dose escalation for continued diabetes management along with diet and exercise.

Precautions:
Use only under medical supervision and avoid in patients with a history of medullary thyroid carcinoma or MEN-2 syndrome. Caution is needed in individuals with pancreatitis, severe gastrointestinal disease, kidney impairment, or those taking other antidiabetic medications due to hypoglycemia risk. Pregnant or breastfeeding women should use it only if advised. Do not inject into swollen, red, or damaged skin.

Adverse Effects:
Possible reactions include nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal discomfort, and mild injection site irritation. Some users may experience dizziness, fatigue, or indigestion. Rare but serious effects may involve pancreatitis, gallbladder problems, hypersensitivity reactions, or kidney function changes.

Storage:
Store in a refrigerator at 2°C to 8°C. Do not freeze. Keep the pen protected from light and heat. If stored at room temperature, follow the stability period mentioned on the pack. Keep out of reach of children.